Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on ArriVent BioPharma, Inc. and keeping the price target at $38.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors including the promising potential of ArriVent BioPharma’s lead candidate, firmonertinib, which is currently in a Phase 3 trial for treating advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The drug has already received Breakthrough Therapy Designation from the FDA, indicating its potential to address an unmet medical need.
Additionally, despite the slight delay in the expected topline data readout to early 2026, the company has completed enrollment for the trial, and management remains optimistic about the outcomes. The anticipated milestones, such as the potential start of a registrational study and proof-of-concept data in 2026, further support the company’s growth prospects. Moreover, ArriVent BioPharma has a solid financial position with approximately two years of cash runway, which provides a stable foundation for its ongoing and future clinical developments.
According to TipRanks, Slutsky is an analyst with an average return of -1.7% and a 37.94% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Cogent Biosciences, and Celldex.
In another report released on July 16, Citi also assigned a Buy rating to the stock with a $40.00 price target.